Introduction {#s1}
============

An estimated 2.1 million lung cancer diagnoses and 1.8 million deaths worldwide were attributed to lung cancer in 2018, accounting for around 11.6% of the total cancer burden, making it the most common cause of cancer-related deaths ([@B10]). According to American Cancer Society statistics for 2017, the numbers of deaths due to lung and bronchus cancers in the United States were estimated to account for around one-quarter of all cancer deaths in 2017 (27% among men and 25% among women) ([@B54]). The five-year survival rate correlated with disease stage at diagnosis, with higher rates of five-year survival for patients with early-stage disease compared with those diagnosed with late-stage disease. Although low-dose computed tomography screening for lung cancer can reduce lung cancer mortality rates by up to 20% as a result of early diagnosis and subsequent early treatment ([@B1]), the five-year survival rate averages only 18% overall, regardless of disease stages ([@B54]).

Chronic obstructive pulmonary disease (COPD) is recognized as being an independent risk factor for lung cancer, with or without smoking ([@B57]). A reduction in averaged forced expiratory volume in one second (FEV~1~) values is associated with increased risks of lung cancer and mortality. Known risk factors that are highly correlated with risk of COPD and lung cancer include cigarette smoking, old age, and familial susceptibility. A review of related mechanisms underlying the disease processes in COPD and lung cancer found that each cigarette puff contains approximately 10^15^ free radicals, including reactive nitrogen and oxygen species (RNOS), which damages DNA and leads to inflammation in multiple pathways ([@B15]). Such inflammation may persist for decades after smoking cessation; aberrant inflammation and immunity has been found to gradually lead to the development of lung cancer ([@B2]; [@B8]). Moreover, telomere shortening has been found in both COPD and lung cancer and short telomere length may undermine the tumor-suppressing mechanism and contribute to inflammatory reaction. COPD is caused by chronic inflammatory response, matrix degradation, apoptosis, remodeling in the airways, and lung parenchyma. Increasing evidence shows that COPD may be a driver of lung cancer. Possible mechanisms involve mitochondrial dysfunction affecting endothelial cell apoptosis, inflammatory mediators influencing the tumor microenvironment, sustained activation of the NF-κB pathway, repeated damage and repair processes that increase the likelihood of EMT and hypoxic status inducing the activation of the alpha subunit of the transcription factor hypoxia-inducible factor-1 (HIF-1α), which is positively correlated with the severity of airflow limitation in COPD and associated with tumor metastasis, angiogenesis, and poor prognosis ([@B59]; [@B15]; [@B39]; [@B8]).

Traditional Chinese medicine (TCM) has been used for centuries to treat the symptoms and signs of COPD, with benefits including a better quality of life, improvement in lung function and a lower risk of exacerbation, and a higher exercise capacity, compared with no TCM use ([@B6]; [@B17]). Chinese herbal medicine (CHM) is an important category of TCM. A meta-analysis of evidence on the anti-inflammatory impact of CHM in patients with COPD has shown that CHM treatment leads to reductions in serum levels of interleukin (IL)-6, IL-8, tumor necrosis factor alpha (TNF-α) and transforming growth factor beta 1 (TGF-β1), as well as decreases in sputum levels of IL-8 and TNF-α ([@B40]). In a cigarette smoke-induced mouse model of COPD, the CHM formula "Liujunzi Tang" indicated that it possesses anti-inflammatory and anti-oxidative properties through its inhibition of NF-κB activation and subsequent protection of lung function ([@B72]). A water-soluble derivative of tanshinone IIA (Tan IIA) appears to decrease levels of cigarette smoke-induced inflammation and oxidative stress by inhibiting the HIF-1α/MAPK signaling pathway ([@B16]). In a randomized controlled trial involving older patients with COPD and FEV~1~/forced vital capacity (FEV) values of less than 70%, significant reductions in serum CRP were observed in the Hochuekkito "Bu-Zhong-Yi-Qi-Tang" treatment group, leading to improvements in systemic inflammation ([@B53]). However, no evidence as yet has reported that CHM treatment in COPD reduces the incidence of lung cancer.

Since its inception in 1995, Taiwan's National Health Insurance (NHI) program has integrated CHM into mainstream medicine. The purpose of this study is to investigate whether the use of CHM in patients with COPD could help to reduce the risk of lung cancer. The study also sought to determine which formulation(s) of CHM appear to be most useful, for future investigations seeking to develop more effective treatments.

Materials and Methods {#s2}
=====================

Study Design and Data Source {#s2_1}
----------------------------

We obtained anonymized, de-identified patient data from the National Health Insurance Research Database (NHIRD) for this retrospective cohort study. The NHIRD has recorded health insurance information from Taiwan's NHI program since 1996. The NHI covers medical procedures such as drugs and surgeries in clinical visit or hospitalizations. TCM outpatient use is also included in the NHI program. This study was approved by the Review Board and Ethics Committee of China Medical University Hospital, Taichung, Taiwan (CMUH104-REC2-115(CR-2)). The review board waived the requirement to sign informed consent from patients, as all of the data were de-identified.

The main data source consists of the Longitudinal Health Insurance Database 2000 (LHID2000), which contains medical care data for a cohort of 1 million insured individuals from 1996 through 2013. Details recorded in the database include the International Classification of Diseases, 9^th^ revision, Clinical Modification (ICD-9-CM) diagnosis codes, details of drug prescriptions and surgery, gender and age.

Subjects {#s2_2}
--------

The study population consisted of patients with COPD (ICD-9-CM codes: 491, 492, 494, and 496) between the years 2000 and 2010, classified into two cohorts according to whether or not they received CHM after a new diagnosis of COPD between 2000 and 2012; Group 1: CHM users, consisting of TCM outpatients with at least 14 days of CHM prescriptions; Group 2: COPD patients with no record of any TCM clinical visits. The study population excluded individuals with any missing basic demographic information or who were aged less than 18 years.

Primary Outcome, Comorbidities, and Demographic Covariates {#s2_3}
----------------------------------------------------------

The primary outcome of this study was a new diagnosis of lung cancer (ICD-9-CM: 162) after COPD. Any life-threatening illnesses such as malignant neoplasms were verified by pathological data. We evaluated the incidence of the following comorbidities at baseline: hypertension (ICD-9-CM: 401-405), stroke (ICD-9-CM: 430-438), coronary artery disease (ICD-9-CM: 410-414), diabetes mellitus (ICD-9-CM: 250), chronic kidney disease (ICD-9-CM: 585), osteoporosis (ICD-9-CM: 733), depression (ICD-9-CM: 296.2, 296.3, 296.82, 300.4, 309.1, 309.28, 311), anxiety (ICD-9-CM: 300), hyperlipidemia (ICD-9-CM: 272), smoking-related diseases (ICD-9-CM: V15.82, 305.1, 794.2, 518.1, 518.3, 518.4) and dementia (ICD-9-CM: 290, 294.1, 331.0), for risk-adjusted outcome analyses. Demographic covariates that were assessed at baseline included gender, age, and work occupations ([**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}).

Propensity Score Matching {#s2_4}
-------------------------

Patients were divided into two groups: those who were prescribed CHM and those who were not. A propensity score was generated for each patient based on gender, age, work occupation and comorbidities, and logistic regression analysis examined the likelihood of lung cancer in the two matched groups.

Statistical Analyses {#s2_5}
--------------------

Baseline characteristics between the CHM and non-CHM cohorts were compared using a Student's *t*-test for continuous variables and a Chi-square test for categorical variables. Cox proportional hazard regression analysis was performed to test for the occurrence of lung cancer. The 10 most commonly prescribed herbs and formulas for treating COPD were selected according to total person-days. We calculated the cumulative incidence rates of lung cancer for the CHM and non-CHM groups using Kaplan-Meier analysis. Network plot demonstrated the usage patterns of each two CHMs, using open-source freeware NodeXL (<http://nodexl.codeplex.com/>). The statistical analysis was run with type I error α = 0.05, using the statistical software package SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

Results {#s3}
=======

Demographic Characteristics {#s3_1}
---------------------------

Of the 81,780 patients with COPD identified in the NHIRD, 11,180 were CHM users and 23,319 were non-CHM users between 2000 and 2010 ([**Figure 1**](#f1){ref-type="fig"}). Fifteen patients in the CHM cohort and 512 in the non-CHM cohort were identified as having lung cancer before the index date and were excluded from analyses. After applying propensity score-matched (1:1) analysis, the final study population consisted of 2,682 CHM users and 2,682 non-CHM users. [**Table 1**](#T1){ref-type="table"} details basic demographic details for each group. In each group, over half of the participants were male (56.1% in the CHM group; 54.9% in the non-CHM group). Compared to non-CHM users, CHM users were older (mean, 57.7 years in the CHM cohort vs 55.9 years in the non-CHM cohort, p \< 0.001) and more likely to have hypertension (p = 0.03).

![Flow chart of study cases identified from 1 million insured individuals in Taiwan between 2000 and 2010.](fphar-10-00987-g001){#f1}

###### 

Demographic characteristics and comorbidities of patients newly diagnosed with COPD in Taiwan during 2000--2010.

                              Non- CHM   CHM    p value          
  --------------------------- ---------- ------ --------- ------ ---------
  **Sex**                                                        0.39
   Female                     1,209      45.1   1,178     43.9   
   Male                       1,473      54.9   1,504     56.1   
  Age at baseline                                                \<0.001
   18--39                     561        20.9   336       12.5   
   40--59                     991        37.0   1,084     40.4   
   ≥60                        1,130      42.1   1,262     47.1   
   Mean(SD)                   55.9       17.9   57.7      14.7   \<0.001
  Job type                                                       0.68
   Office workers             1,299      48.4   1,267     47.2   
   Manual workers             1,124      41.9   1,149     42.8   
   Others                     259        9.7    266       9.9    
  Baseline comorbidity                                           
   Hypertension               1,092      40.7   1,170     43.6   0.03
   Stroke                     178        6.6    186       6.9    0.66
   Coronary artery disease    624        23.3   676       25.2   0.10
   Hyperlipidemia             735        27.4   746       27.8   0.74
   Diabetes mellitus          259        9.7    272       10.1   0.55
   Chronic kidney disease     60         2.2    58        2.2    0.85
   Osteoporosis               312        11.6   354       13.2   0.08
   Depression                 168        6.3    194       7.2    0.16
   Anxiety                    568        21.2   605       22.6   0.22
   Dementia                   45         1.7    39        1.5    0.51
   Smoking related diseases   11         0.4    13        0.5    0.68

Chi-square test, ‡Student's t test.

CHM, Chinese herbal medicine; SD, standard deviation.

Cause-Specific Hazard Ratios and 10-Year Cumulative Incidence of Lung Cancer {#s3_2}
----------------------------------------------------------------------------

A total of 46 lung cancer events occurred among CHM users and 64 among non-CHM users ([**Table 2**](#T2){ref-type="table"}). COPD patients using CHM treatment had a significantly lower risk for lung cancer compared with non-CHM users (adjusted hazard ratio \[aHR\] = 0.36, 95% CI = 0.24--0.53, p \< 0.001). The risk of lung cancer was significantly higher for patients aged 40--59 years (aHR = 5.32, 95% CI = 2.19--12.94, p \< 0.001) and those aged ≥60 years (aHR = 16.75, 95% CI = 7.54--37.23, p \< 0.001) compared with patients aged 18--39 years (reference population). Type of occupation did not significantly affect the risk of developing lung cancer, whether COPD patients were receiving CHM treatment or not. We used Kaplan-Meier estimates to calculate cumulative incidence of lung cancer for the CHM and non-CHM groups over the 10-year follow-up period, adjusting for patients' age, gender, type of occupation, and comorbidities. The cumulative incidence of lung cancer was significantly lower among CHM users than among non-CHM users (Log-rank test, p \< 0.001) ([**Figure 2**](#f2){ref-type="fig"}).

###### 

Cox model measured hazard ratio and 95% confidence intervals of lung cancer associated with and without CHM and covariates among COPD patients.

  Characteristics                    Event no.   Crude   Adjusted                                          
  ---------------------------------- ----------- ------- --------------- --------- ------- --------------- ---------
  CHM                                                                                                      
   No                                64          1       reference                 1       reference       
   Yes                               46          0.47    (0.32--0.69)    \<0.001   0.36    (0.24--0.53)    \<0.001
  Sex                                                                                                      
   Female                            43          1       reference                 1       reference       
   Male                              67          1.22    (0.83--1.79)    0.30      1.32    (0.88--1.99)    0.18
  Age at baseline                                                                                          
   18--39                            7           1       reference                 1       reference       
   40--59                            17          3.81    (1.58--9.20)    0.003     5.32    (2.19--12.94)   \<0.001
   ≥60                               86          10.50   (4.86--22.69)   \<0.001   16.75   (7.54--37.23)   \<0.001
  Job type                                                                                                 
   Office workers                    42          1       reference                 1       reference       
   Manual workers                    58          1.68    (1.13--2.50)    0.01      1.39    (0.93--2.08)    0.10
   Others                            10          1.23    (0.62--2.45)    0.56      0.93    (0.46--1.86)    0.83
  Baseline comorbidity (Yes vs No)                                                                         
   Hypertension                      47          1.07    (0.73--1.56)    0.74      0.65    (0.43--0.99)    0.05
   Stroke                            4           0.64    (0.23--1.73)    0.37      0.50    (0.18--1.39)    0.19
   Coronary artery disease           35          1.54    (1.03--2.31)    0.03      1.20    (0.78--1.85)    0.41
   Diabetes mellitus                 8           0.76    (0.37--1.57)    0.46      0.69    (0.33--1.44)    0.32
   Hyperlipidemia                    30          0.97    (0.64--1.48)    0.89      0.82    (0.53--1.28)    0.39
   Chronic kidney disease            2           0.97    (0.24--3.93)    0.97      1.03    (0.25--4.23)    0.97
   Osteoporosis                      16          1.30    (0.77--2.22)    0.33      1.07    (0.6--1.88)     0.83
   Depression                        3           0.40    (0.13--1.27)    0.12      0.62    (0.18--2.09)    0.44
   Anxiety                           16          0.61    (0.36--1.04)    0.07      0.60    (0.34--1.06)    0.08
   Dementia                          1           0.88    (0.12--6.32)    0.90      0.71    (0.10--5.17)    0.73
   Smoking related diseases          1           2.65    (0.37--19.04)   0.33      3.53    (0.48--25.75)   0.21

HR, hazard ratio; CI, confidence interval; CHM, Chinese herbal medicine.

Adjusted HR: adjusted for gender, age, type of occupation, and all comorbidities in Cox proportional hazards regression.

![Comparison of Kaplan-Meier estimates of the 10-year cumulative incidence of lung cancer in COPD patients with and without CHM usage (Log-rank test, p \< 0.001).](fphar-10-00987-g002){#f2}

The Top 10 Single Herbs and Formulas Used in CHM Prescriptions {#s3_3}
--------------------------------------------------------------

The 10 most commonly used single herbs in COPD patients were *Fritillaria thunbergii*, *Prunus armeniaca*, *Platycodon grandiflorus*, *Scutellaria baicalensis*, *Ophiopogon japonicus*, *Houttuynia cordata*, *Salvia miltiorrhiza*, *Glycyrrhiza uralensis*, *Tussilago farfara*, and *Magnolia officinalis* ([**Table 3**](#T3){ref-type="table"}). Xiao Qing Long Tang, Zhi Sou San, Mai Men Dong Tang, Ma Xing Gan Shi Tang, Ding Chuan Tang, Bai He Gu Jin Tang, Xin Yi Qing Fei Tang, Qing Zao Jiu Fei Tang, Qing Fei Tang, and Xin Yi San were the 10 most common formulas used for COPD patients ([**Table 4**](#T4){ref-type="table"}). Approximately 30% of prescriptions for COPD patients contained five or six CHMs ([**Figure 3**](#f3){ref-type="fig"}). COPD patients most often received prescriptions containing three to eight CHMs. The most common combination of single herbs was *F. thunbergii* and *P. armeniaca*, followed by *F. thunbergii* and *P. grandiflorus*. Xiao Qing Long Tang was the most common formula to be combined with other CHMs ([**Figure 4**](#f4){ref-type="fig"}).

###### 

Ten most common herbs prescribed for patients with COPD.

  ----------------------------------------------------------------------------------------------------------------------------------------
  Scientific name (Chinese name)   Frequency   Number of person-days   Average daily dose (g)   Average duration for prescription (days)
  -------------------------------- ----------- ----------------------- ------------------------ ------------------------------------------
  Fritillaria thunbergii\          7,611       74,223                  1.3                      9.8
  (Zhe-Bei-Mu)                                                                                  

  Prunus armeniaca\                5,902       58,205                  1.2                      9.9
  (Xing-Ren)                                                                                    

  Platycodon grandiflorus\         5,380       56,919                  1.6                      10.6
  (Jie-Geng)                                                                                    

  Scutellaria baicalensis\         3,146       31,050                  1.2                      9.9
  (Huang-Qin)                                                                                   

  Ophiopogon japonicus\            2,641       28,296                  2.9                      10.7
  (Mai-Men-Dong)                                                                                

  Houttuynia cordata\              2,886       27,082                  1.4                      9.4
  (Yu-Xing-Cao)                                                                                 

  Salvia miltiorrhiza\             1,831       25,080                  1.7                      13.7
  (Dan-Shen)                                                                                    

  Glycyrrhiza uralensis\           2,063       21,753                  1.4                      10.5
  (Gan-Cao)                                                                                     

  Tussilago farfara\               2,430       21,681                  1.2                      8.9
  (Kuan-Dong-Hua)                                                                               

  Magnolia officinalis\            1,867       21,558                  1.3                      11.5
  (Hou-Po)                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------

###### 

Ten most common formulas prescribed for patients with COPD.

  Formula name            Frequency   Number of person-days   Average daily dose (g)   Average duration for prescription (days)
  ----------------------- ----------- ----------------------- ------------------------ ------------------------------------------
  Xiao Qing Long Tang     7,407       82,110                  5                        11.1
  Zhi Sou San             6,180       51,301                  4.6                      8.3
  Mai Men Dong Tang       4,750       44,566                  5.1                      9.4
  Ma Xing Gan Shi Tang    5,085       41,541                  6.5                      8.2
  Ding Chuan Tang         3,878       40,226                  7.2                      10.4
  Bai He Gu Jin Tang      3,601       35,653                  8.3                      9.9
  Xin Yi Qing Fei Tang    3,035       32,173                  5.8                      10.6
  Qing Zao Jiu Fei Tang   3,048       30,848                  5.7                      10.1
  Qing Fei Tang           2,602       25,936                  5.9                      10
  Xin Yi San              2,268       25,623                  6.8                      11.3

![Distribution of Chinese herbal medicine combinations in one treatment for all patients with COPD.](fphar-10-00987-g003){#f3}

![Network analyses of the most frequent 30 herbs and formulas combinations for all patients with COPD. The size of spot indicates the frequency of Chinese herbal product and the width of line indicates the combination time of two Chinese herbal products.](fphar-10-00987-g004){#f4}

The Degree of CHM Exposure as Treatment Duration {#s3_4}
------------------------------------------------

We have analysed the degree of exposure as CHM treatment duration. In this study, all CHM users were those with more than 14 days of CHM prescriptions. The risk of lung cancer was associated with cumulative use (in days) of CHM. Compared to non-CHM users, CHM users who had between 28 and 60 days of CHM were at lower risk of developing lung cancer (aHR = 0.32, 95% CI = 0.18--0.57) ([**Table 5**](#T5){ref-type="table"}).

###### 

Hazard Ratios and 95% confidence intervals of lung cancer risk associated with cumulative use day of CHM among COPD patients.

  ----------------------------------------------------------------------------------------------------------
                           Event no.\   Person-year   IR      Hazard ratio (95% CI)   
                           (n = 110)                                                  
  ------------------------ ------------ ------------- ------- ----------------------- ----------------------
  **Non-CHM users**        64           12,527        51.09   Ref.                    Ref.

  **Chinese herb users**                                                              

  14-28 days               12           4,494         26.70   0.60(0.32--1.11)        0.53(0.28--1.02)

  28-60 days               14           8,625         16.23   0.36(0.20--0.65)\*\*    0.32(0.18--0.57)\*\*

  \>60 days                20           8,602         23.25   0.52(0.31--0.86)\*      0.41(0.25--0.69)\*\*
  ----------------------------------------------------------------------------------------------------------

Crude HR^＊^ represented relative hazard ratio; Adjusted HR^†^ represented adjusted hazard ratio: mutually adjusted for age, gender, job type and comorbidities in Cox proportional hazard regression.

\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

CHM, Chinese herbal medicine; CI, confidence interval; IR, incidence rates.

Risk of Incident Lung Cancer According to Use of Western Medicine and CHM {#s3_5}
-------------------------------------------------------------------------

We compared the risk of incident lung cancer according to use/non-use of Western medicine and CHM ([**Table 6**](#T6){ref-type="table"}). In analyses adjusted for demographic and comorbidity factors, patients using only CHM were at significantly lower risk of developing lung cancer compared to patients using Western medications for COPD (long-acting beta agonists \[LABAs\], long-acting muscarinic antagonists \[LAMAs\], short-acting beta-agonists \[SABAs\], short-acting muscarinic antagonists \[SAMAs\] and inhaled corticosteroids \[ICS\]) and no CHM (p \< 0.001 for all comparisons). Moreover, patients using ICS combined with CHM were also at lower risk of lung cancer (aHR = 0.43, 95% CI = 0.20--0.92). However, patients using SABAs without CHM treatment had a significantly higher risk of developing lung cancer (aHR = 2.25, 95% CI = 1.32--3.84).

###### 

Cox proportional hazard regression analysis for the risk of lung cancer associated with COPD medication.

  Variable   Event      Person years   IR       Crude HR (95% CI)   Adjusted HR (95% CI)     
  ---------- ---------- -------------- -------- ------------------- ------------------------ ------------------------
  **CHM**    **LABA**                                                                        
  No         No         59             11,840   49.83               Ref.                     Ref.
  No         Yes        5              687      72.77               1.55(0.62--3.88)         1.32(0.53--3.31)
  Yes        No         38             19,787   19.20               0.44(0.30--0.66)\*\*\*   0.38(0.25--0.58)\*\*\*
  Yes        Yes        8              1,935    41.35               0.96(0.46--2.01)         0.55(0.261.18)
  **CHM**    **LAMA**                                                                        
  No         No         60             12,285   48.84               Ref.                     Ref.
  No         Yes        4              242      165.11              3.64(1.32--10.03)\*      2.48(0.89--6.93)
  Yes        No         42             20,901   20.09               0.47(0.32--0.70)\*\*\*   0.40(0.27--0.60)\*\*\*
  Yes        Yes        4              820      48.77               1.13(0.41--3.12)         0.57(0.20--1.61)
  **CHM**    **SABA**                                                                        
  No         No         42             11,043   38.03               Ref.                     Ref.
  No         Yes        22             1,484    148.25              3.38(2.01--5.67)\*\*\*   2.25(1.32--3.84)\*\*
  Yes        No         26             18,478   14.07               0.41(0.25--0.67)\*\*\*   0.35(0.21--0.58)\*\*\*
  Yes        Yes        20             3,243    61.67               1.80(1.05--3.07)\*       1.06(0.60--1.85)
  **CHM**    **SAMA**                                                                        
  No         No         50             11,433   43.73               Ref.                     Ref.
  No         Yes        14             1,094    128.01              2.48(1.37--4.50)\*\*     1.50(0.81--2.77)
  Yes        No         28             19,252   14.54               0.37(0.23--0.59)\*\*\*   0.32(0.20--0.51)\*\*\*
  Yes        Yes        18             2,470    72.88               1.84(1.07--3.17)\*       0.98(0.56--1.73)
  **CHM**    **ICS**                                                                         
  No         No         59             11,578   50.96               Ref.                     Ref.
  No         Yes        5              949      52.68               1.09(0.44--2.72)         0.89(0.35--2.22)
  Yes        No         38             19,143   19.85               0.45(0.30--0.67)\*\*\*   0.39(0.25--0.59)\*\*\*
  Yes        Yes        8              2,579    31.02               0.70(0.33--1.46)         0.43(0.20--0.92)\*

IR, incidence rates, per 10,000 person-years; HR, hazard ratio; CI, confidence interval; LABA, long-acting beta-agonists; LAMA, long-acting muscarinic antagonists; SABA, short-acting beta-agonists; SAMA, short-acting muscarinic antagonists; ICS, inhaled corticosteroids.

Adjusted HR: adjusted for gender, age, job type and all comorbidities in Cox proportional hazards regression.

\*p value \< 0.05; \*\*p value \< 0.01; \*\*\*p value \< 0.001.

Discussion {#s4}
==========

COPD is a persistently inflammatory response in the airways and lung parenchyma accompanied by excess mucus secretion, fibrosis, and proteolysis, leading to the clinical phenotypes of chronic bronchitis, airway obstruction, and emphysema ([@B38]). COPD increases the risk of lung cancer ([@B57]). In an investigation of cancer trends in COPD patients in primary care settings, the annual incidence rate of lung cancer was 4-fold to 5-fold higher in patients with COPD compared with the general population; moreover, the COPD cohort had worse 3-year survival from lung cancer than those in the general population ([@B26]). Smoking is the main risk factor for COPD and lung cancer ([@B9]). Other risk factors include long-term exposure to air pollution, occupational dust, previous tuberculosis, early childhood recurrent lower respiratory infections, poor nutrition, and old age ([@B9]). Quitting smoking is the best way to prevent COPD and lung cancer ([@B56]; [@B62]). The number of global COPD cases continues to increase: a recent meta-regression analysis estimated a global COPD prevalence of 10.7% (7.3%--14.0%) in 1990 and 11.7% (8.4%--15.0%) in 2010, with 2.27 million and 3.84 million affected cases in 1990 and 2010, respectively ([@B3]).

Our study revealed significantly higher rates of hypertension (p = 0.03) among CHM users than among non-CHM users ([**Table 1**](#T1){ref-type="table"}). In Taiwan, TCM is commonly used to assist in the treatment of these diseases. Some studies have mentioned that arterial hypertension may be related to the development of renal cell carcinoma, but not lung cancer ([@B27]; [@B48]). In our study, the mean age of patients in the CHM cohort was significantly older than those in the non-CHM cohort (57.7 years vs 55.9 years; p \< 0.001). Statistical analyses have indicated that age is an independent risk factor for lung cancer, particularly age above 60 years ([@B50]; [@B51]). These findings are consistent with our study data; older age was positively correlated with the risk of lung cancer ([**Table 2**](#T2){ref-type="table"}). However, this pattern was reversed in the CHM group, who had a lower risk of lung cancer.

Modern medicine provides diverse treatment modalities for COPD. Bronchodilators alone or in combination with anti-inflammatory agents, such as corticosteroids, are the main therapeutic strategy. We compared the effects of Western medicine and CHM on the risk of developing lung cancer in COPD patients ([**Table 6**](#T6){ref-type="table"}). Some reports have suggested that regular use of ICS in COPD patients may reduce the risk of lung cancer ([@B45]; [@B25]; [@B49]), which is consistent with our research. However, long-term exposure to steroids is associated with severe side effects including severe infection such as pneumonia or steroid-induced fractures ([@B37]; [@B55]). Moreover, COPD patients with tuberculosis or pneumonia are at increased risk of lung cancer after using ICS ([@B64]). COPD treatment guidelines emphasize the need to lower comorbidities and risk of exacerbations, as well as increase the quality of life and exercise capacity of patients ([@B47]). Control of COPD disease without treatment-related side effects is essential and this has resulted in the concurrent use of CHM and conventional Western medical treatment in Taiwan. A LABA/LAMA combination can reduce COPD exacerbations and effectively improve symptoms and quality of life scores ([@B43]). It is also the best combination to improve FEV~1~ ([@B7]). A population-based study has mentioned that the combination of a LAMA and a LABA may increase the risk of stroke compared with use of either agent alone ([@B61]). These agents are deemed to be safe when used appropriately in COPD patients without uncontrolled cardiovascular disease or other notable comorbidities ([@B30]). However, as shown in this study ([**Table 6**](#T6){ref-type="table"}), the use of LABAs, LAMAs, SABAs or SAMAs as monotherapy were associated with an apparently higher risk of lung cancer. With the addition of CHM to these agents, the risk of lung cancer was reduced. This novel, important finding needs to be confirmed with further, more rigorous research.

In TCM theory, use of Chinese medicine is determined by "syndrome differentiation and treatment". The three most commonly used CHM herbs are *F. thunbergii* (Zhe-Bei-Mu), *P. armeniaca* (Xing-Ren), and *P. grandiflorus* (Jie-Geng). *F. thunbergii* is used to expel heat and phlegm in TCM treatment; this herb has also shown antitussive, expectorant, and anti-inflammatory effects in murine models ([@B63]). *P. armeniaca* is used to relieve coughing and gasping for breath, to nourish the lungs, and to relieve constipation. *P. grandiflorus* facilitates flow of lung-*qi*, relieves sore throat, eliminates sputum, and expels pus from the lungs and throat. *P. grandiflorus* root-derived saponin inhibits acrolein-induced expression of mucin 5 and inhibits reactive oxygen species (ROS) formation ([@B14]). Flavones of *S. baicalensis* (Huang-Qin) have demonstrated an anti-cancer effect by arresting the cell cycle and suppressing the inflammatory environment and production of oxygen-derived radicals ([@B34]). *O. japonicus* (Mai-Men-Dong) is used to nourish the yin and moisten the lung. Study evidence has revealed a wide range of pharmacologic activities associated with *O. japonicus*, including anti-oxidation, anti-inflammation, cardiovascular protection, cough relief, immunoregulatory, and antidiabetic properties, and antitumor activity ([@B11]). Ophiopogonin D', a bioactive saponin compound isolated from *O. japonicus*, induces cell apoptosis by inhibiting the nuclear factor (NF)-κB pathway or suppressing the STAT3 signaling pathway and downregulating the expression of oncogenic genes ([@B32]; [@B33]). *H. cordata* (Yu-Xing-Cao) clears away heat, detoxifies, eliminates phlegm, and drains pus. In a mouse model of lipopolysaccharide (LPS)-induced acute lung injury (ALI), *H. cordata* and flavonoid constituents, including afzelin, hyperoside and quercitrin, inhibit lung inflammatory responses ([@B31]). In a cigarette smoke and LPS-induced COPD rat model, sodium houttuyfonate, an active compound extracted from *H. cordata Thunb*, is associated with marked anti-inflammatory effects related to suppression of the toll-like receptor 4 (TLR4)/NF-κB pathway ([@B66]). *S. miltiorrhiza*(Dan-Shen) is used to relieve pain, promote blood circulation, and nourish blood. Many studies have shown that *S. miltiorrhiza* or its extract has antioxidative, anti-inflammatory, and even antitumor activities ([@B22]; [@B67]). Moreover, *S. miltiorrhiza* components such as Tan IIA can markedly reduce the area of collagen deposition in bleomycin-induced pulmonary fibrosis and inhibit TGF-β1-triggered alveolar EMT in rat models, indicating a positive effect for prevention and treatment of lung fibrotic change associated with COPD ([@B18]; [@B58]). Traditionally, *G. uralensis* (Gan-Cao) has been used to replenish *qi*, clear away heat, detoxify, relieve cough, and reconcile various medicines. The major antitussive and expectorant compounds extracted from *G. uralensis* are liquiritin apioside and liquiritin, which can significantly decrease cough frequency ([@B29]). Glycyrrhizin not only decreases levels of pro-inflammatory cytokines such as interleukin (IL)-1β and TNF-α, but also suppresses the expression of cyclooxygenase-2 (COX-2) and iNOS, reducing the severity of LPS-induced ALI in mice ([@B42]), and improves long-term histopathologic changes in a murine model of asthma ([@B19]). *T. farfara* (Kuan-Dong-Hua) is one of the major ingredients of the TCM formulas Zhi Sou San and Ding Chuan Tang, which have proven significant antitussive, expectorant, and anti-inflammatory effects in recent pharmacological research ([@B65]). Recent *in vitro* investigations have shown that tussilagone, a natural product derived from *T. farfara*, inhibits the production of mucin protein and downregulates the expression of the mucin gene in airway epithelial cells *via* the NF-κB signaling pathway ([@B13]). *M. officinalis* (Hou-Po) is used to regulate *qi* and eliminate flatulence. It is traditionally believed that intestinal gas also affects the function of lungs. Recent studies have revealed that the product magnolol, purified from *M. officinalis*, has antioxidant, anti-inflammatory, and antitumor effects, even inducing apoptosis in non-small cell lung cancer (NSCLC) cells ([@B60]).

Xiao Qing Long Tang (XQLT), the most commonly used formula in our study, is capable of downregulating pro-inflammatory cytokines, iNOS expression and NF-kB phosphorylation in cigarette smoke concentrate-stimulated human airway epithelial cells ([@B52]). In another study, XQLT inhibited the growth of A549 cells in NSCLC by inducing cell apoptosis ([@B46]). Zhi Sou San and Mai Men Dong Tang both act as antitussive agents. In the treatment of cough, compared to conventional cough medicines, Zhi Sou San was associated with fewer adverse effects and a lower recurrence rate ([@B12]). Mai Men Dong Tang attenuates cough severity in chronic cough of COPD ([@B41]) and minimizes airway hyper-responsiveness by suppressing the release of vagal neuroeffector transmitters ([@B4]; [@B5]). Ma Xing Gan Shi Tang and Ding Chuan Tang have traditionally been used to treat cough or asthma in the pattern of "lung heat". In acute exacerbations of COPD, Ding Chuan Tang combined with Western anti-infective agents can effectively control clinical symptoms, reduce the recurrence rate and improve lung function ([@B24]). In another clinical study examining acute exacerbations of COPD, Ma Xing Gan Shi Tang combined with conventional treatment lowered TNF-α and IL-6 concentrations and increase FEV~1~% and FEV~1~/FVC% ([@B21]). In a mouse model of H1N1 influenza A virus-associated ALI, Ma Xing Gan Shi Tang ameliorates lung cell apoptosis and downregulates serum TNF-α concentrations ([@B71]). Bai He Gu Jin Tang is commonly used in the "lung and kidney yin deficiency" type of lung diseases, although there are few studies related to COPD. However, investigations using modified Bai He Gu Jin Tang to treat lung cancer have indicated increased efficacy and reduced toxicity of chemotherapy, with an improved quality of life ([@B20]; [@B36]). Xin Yi Qing Fei Tang and Xin Yi San have often been used in allergic rhinitis, acute and chronic rhinitis, sinusitis, and other such conditions, but few studies are related to COPD ([@B69]; [@B70]). Qing Zao Jiu Fei Tang is used to treat the lung disease of "dry evil injured lung syndrome", and is good for coughing. In an evaluation of TCM combined with conventional cancer treatment for lung cancer, Qin Zao Jiu Fei Tang was the most effective TCM for mortality reduction (HR = 0.81; 95% CI = 0.72--0.91) ([@B35]). *In vitro* and *in vivo* studies have revealed that the molecular mechanisms underlying the antitumor activities of Qin Zao Jiu Fei decoction are associated with the upregulation of p53 mRNA and downregulation of c-myc and Bcl-2 mRNA expression, as well as suppression of matrix metallopeptidase 9 (MMP-9), vascular endothelial growth factor (VEGF), and VEGF receptor protein expression ([@B68]). In Japan, Qing Fei Tang (Seihai-to) has been found to increase airway ciliary beat frequency ([@B28]) and reduce oxygen radical production in inflamed lungs of rats ([@B23]). All of these herbs and formulas have been used to alleviate clinical symptoms, decrease inflammation and/or prevent carcinogenesis in COPD patients, based on both TCM theory and scientific studies, thus, a summary of common formulas and herbs is given in [**Supplementary Table 2**](#SM2){ref-type="supplementary-material"}. When compared with conventional treatment alone in stable COPD, TCM combined with conventional treatment is associated with improvements in FEV~1~, the six-minute-walk, St George's Respiratory Questionnaire (SGRQ) scores and fewer exacerbations ([@B17]). To our knowledge, chronic inflammation, including increased oxidative stress, persistent exposure to pro-inflammatory cytokines and an impaired DNA repair mechanism, is a leading cause of lung cancer, to the same extent as is seen with COPD progression. ([@B15]).

Our study evidence suggests that the duration of CHM exposure in COPD is important: patients used CHM for more than 28 days had a significantly reduced risk of lung cancer compared with non-CHM users. This is worthy of further investigation in clinical observational studies.

Whether TCM treatment lowers the risk of lung cancer in patients with COPD is unclear. Our study evidence shows that CHM not only reduces COPD-related symptoms, but also has antitumor effects by relieving oxidative stress, reducing tumor cell apoptosis and lowering concentrations of pro-inflammatory cytokines. According to a previous study, tumor progression in NSCLC correlates with tumor-associated macrophages (TAMs), which are regulated by IL-10 and programmed death-ligand 1 (PD-L1) ([@B44]). In that study, CHM not only showed inhibitory effects upon TAMs in the tumor microenvironment, but also alleviated lung cancer-related symptoms ([@B44]).

There are some noteworthy limitations in this study. The NHIRD dataset does not contain details of body mass index values, levels of physical activity, environmental/chemical exposure, or family medical history. In addition, the NHIRD does not provide more detailed clinical evaluations including COPD assessment or pulmonary function tests, serum laboratory data, imaging data, pathological reports or cancer staging. Nevertheless, this large-scale, population-based, retrospective cohort study offers valuable insights into the effectiveness of CHM combined with Western medicine in the reduction of risk for lung cancer among patients with COPD.

Conclusion {#s5}
==========

In conclusion, COPD and lung cancer could represent different symptoms and signs, with the same predisposition. Our findings suggest that CHM might retard the progression of COPD to lung cancer and that CHM could provide a new treatment option for patients with COPD. In combination with Western medicine for the treatment of COPD, CHM may reduce the incidence of lung cancer. Further studies are warranted to explore the possible antitumor effects and associated mechanisms of CHM treatment in patients with COPD.
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